Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companiesStrong track record of launching breakthrough technologies across spine, neurosurgery and pain managementStrengthens Aclarion’s commercial execution as the Company expands adoption and payer engagement across the Eastern U.S. BROOMFIELD, Colo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare techn ...

Core Insights - VEON Ltd. has received two prestigious awards at the IR Magazine Corporate Governance Awards 2025, recognizing its governance excellence and innovative use of technology in corporate governance [1][5] Group 1: Awards and Recognition - The "Best Governance Around a Corporate Transaction" award acknowledges VEON's exemplary governance during the successful listing of Kyivstar Group Ltd. on Nasdaq in August 2025 [5] - The "Best Use of Technology" award highlights VEON's innovative integration of augmented intelligence and digital tools in enhancing its governance framework [5] Group 2: Leadership and Commitment - Kaan Terzioglu, VEON Group CEO, expressed pride in the recognition of VEON's commitment to governance excellence, attributing it to the teams involved in the Kyivstar listing and the Board of Directors' oversight [2] - The recognition validates the extensive efforts in structuring the Kyivstar listing to uphold robust governance principles and protect investor interests, marking a historic achievement as Kyivstar became the first Ukrainian company to list on a U.S. stock exchange [3] Group 3: Company Overview - VEON is a digital operator providing connectivity and digital services to nearly 160 million customers across five countries, contributing to economic growth through technology-driven services [4]

Financial Data and Key Metrics Changes - Company reported total revenue of $1.115 billion for Q3 2025, reflecting a year-on-year growth of 7.5% in USD terms [24] - EBITDA for the quarter was $524 million, representing a growth of 19.7%, with an EBITDA margin of 47%, up 400 basis points year-on-year [25] - Last 12-month EPS stands at $8.89, up 60.2% year-on-year, although reported EPS for Q3 alone was a loss of $1.84 per share due to non-cash charges [8][9] Business Line Data and Key Metrics Changes - Direct digital revenues grew 63% year-on-year to reach $198 million, now accounting for 17.8% of total revenues, up from 11% a year ago [25] - Telecom and infrastructure segment revenues grew 3.5% on a like-for-like basis, reflecting the impact of differentiated networks and services [8] - Multiplay customers generated 3.8 times the ARPU of voice-only subscribers, with 55.4% of total customer revenues coming from this segment, which grew revenue-wise by 23% year-on-year [12][13] Market Data and Key Metrics Changes - Strong double-digit revenue growth was delivered across all markets except Bangladesh, which saw a return to year-on-year growth for the first time in 14 months [14] - In Pakistan, the financial services business gross transaction value rose 40% year-on-year, representing 13% of the country's GDP [15] - The digital-only user base has more than doubled to 50 million, representing nearly 35% of total digital users [17] Company Strategy and Development Direction - The company is focused on a digital operator model, combining connectivity, digital platforms, and financial inclusion to unlock sustainable growth [4] - The asset-light strategy continues with the sale of Kyrgyzstan operations and a global framework agreement with Starlink for satellite connectivity [6] - The company is exploring opportunities for further investment in Ukraine, aligning with its "Invest in Ukraine Now" initiative [35] Management's Comments on Operating Environment and Future Outlook - Management raised the fiscal year 2025 EBITDA outlook to 16%-18% growth in local currency terms, up from 14%-16% [4] - The company remains confident in its growth trajectory despite macro and geopolitical challenges, with a focus on sustaining long-term value creation [29][30] - Management emphasized the importance of operational cost management and disciplined pricing actions in supporting margin improvements [58] Other Important Information - The company completed the operational separation of JazzCash, enhancing growth potential in digital financial services [15] - A $100 million share and/or bond repurchase program was approved by the board, reflecting confidence in growth prospects [7] - The company ended the quarter with a cash balance of $1.67 billion, including $653 million at headquarters [26] Q&A Session Summary Question: Motivation for Kyivstar's SPAC transaction - Management chose a SPAC structure for its deal certainty and speed, believing it was the right move to list Kyivstar successfully [34] Question: Plans for cash at headquarters - The cash at headquarters is $653 million, with limitations on upstreaming due to martial law in Ukraine, focusing on investments in the country [38] Question: Future of tower assets in Ukraine - The company aims to pursue divestment of tower assets in Ukraine, similar to its strategy in Pakistan, to enhance cash generation [45] Question: Financial services in Pakistan - The financial services business targets unbanked individuals, with microloans providing essential support to small businesses [49] Question: Growth of JazzCash and MMBL - The company plans to leverage capabilities from JazzCash and MMBL to expand fintech services in other markets, focusing on smartphone penetration [72] Question: Ride-hailing market expansion - The company has ambitions to grow its ride-hailing business in other markets, with a city-by-city operational strategy [80] Question: Trade-off between scale and profitability - Management noted that digital services have not diluted EBITDA margins as expected, attributing this to operational cost discipline [58] Question: Run rate for financial services EBITDA - The financial services business has shown steady growth, with expectations for continued performance in the coming quarters [95]

Core Insights - Aclarion, Inc. has appointed Dan Isherwood as UK Commercial Director, marking a significant commercial milestone for the company [2][3] - The UK market is the first where physicians can order Nociscan without payment concerns, potentially benefiting over 5 million patients [2][6] - Nociscan has gained traction in the UK, being covered by three of the four top private insurers, reaching over 5.2 million covered lives [2][6] Company Overview - Aclarion is a healthcare technology company utilizing biomarkers and proprietary AI algorithms to assist in identifying chronic low back pain [1][5] - The company's Nociscan solution is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and nonpainful discs in the lumbar spine [4][5] - Nociscan employs Magnetic Resonance Spectroscopy (MRS) to analyze data and quantify chemical biomarkers associated with disc pain [5][6] Market Potential - An estimated 266 million people globally suffer from chronic low back pain, highlighting a significant health challenge [4] - The appointment of Dan Isherwood is expected to accelerate the adoption of Nociscan in the UK, leveraging his extensive experience in advanced imaging and spine technologies [3][6] - Aclarion aims to strengthen relationships with physicians and imaging centers as part of its UK commercial expansion strategy [2][3]

Core Insights - Aclarion, Inc. has been recognized as a Rising Star in the Clinical Diagnostic Device category at the 2025 Digital Health Awards, highlighting its innovative Nociscan solution for chronic low back pain [1][3][4] Company Overview - Aclarion is a healthcare technology company that utilizes biomarkers and proprietary augmented intelligence algorithms to assist physicians in identifying the sources of chronic low back pain [1][6] - The company's Nociscan solution is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and non-painful discs in the lumbar spine [4][6] Product Details - Nociscan transforms magnetic resonance spectroscopy (MRS) signals into objective biomarkers associated with disc pain, providing actionable insights for personalized treatment plans [5][6] - An estimated 266 million people globally suffer from chronic low back pain, indicating a significant market opportunity for Aclarion's technology [5] Industry Recognition - The Digital Health Awards celebrate advancements in the digital health sector, with Aclarion's recognition from over 1,800 submissions underscoring its commitment to improving healthcare efficiency and equity [3][6]

Core Insights - Aclarion, Inc. has a debt-free balance sheet with $13.3 million in cash, equating to $15.11 per share fully diluted, providing strategic flexibility for growth [1][9] - Nociscan scan volumes have increased by 89% year-over-year, marking the third consecutive quarter of record utilization across U.S., U.K., and E.U. markets [1][4] - The CLARITY pivotal trial is progressing on schedule, with early three-month readouts expected in Q2 2026 as AI-driven disc pain biomarker validation continues [1][3] Market Adoption & Growth Momentum - Nociscan scan volumes increased by 89% year-over-year in Q3, indicating strong physician adoption and commercial traction [4] - The technology was featured at the International Society of Pain and Neuroscience annual meeting, validating its importance in chronic low back pain diagnosis [4] - Aclarion was named a finalist in the Rising Star – Clinical Diagnostic Device category at the 2025 Digital Health Awards, further validating Nociscan's innovation [4] Key Value Catalyst: CLARITY Trial Progress & AI Algorithm Validation - The CLARITY trial is on track, with the first patients enrolled at UHealth-University of Miami Health System, aiming for full enrollment by Q4 2026 [4] - The trial is designed to quantify the clinical value of integrating Nociscan data into surgical planning, targeting outcomes that exceed the current industry benchmark of approximately 54% [4] - Early internal interim data readout is expected in Q2 2026, providing a high-visibility catalyst as patient data accumulates [4] Leadership & Financial Strength Catalyst - The appointment of Greg Gould as CFO strengthens the leadership team at a pivotal inflection point for the company [6][9] - Aclarion's financial discipline remains a core priority, with capital allocation aligned to high-return milestones across commercial and clinical initiatives [9] - The company is focused on operational leverage, strategic partnerships, and scalable revenue models to unlock long-term shareholder value [9]

Core Insights - Aclarion, Inc. presented its Nociscan® solution at the ISPN Annual Meeting, emphasizing its role in diagnosing chronic low back pain through disc chemistry analysis [1][5] - Nociscan is the first evidence-supported SaaS platform that noninvasively differentiates between painful and non-painful discs in the lumbar spine, providing actionable insights for personalized treatment [2][4] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing Magnetic Resonance Spectroscopy (MRS) and proprietary AI algorithms to optimize clinical treatments [4][6] - The company aims to establish Nociscan as the gold standard for identifying sources of chronic low back pain, addressing a global issue affecting over 266 million people [5][6] Technology and Innovation - Nociscan converts MR spectroscopy signals into objective biomarkers associated with disc pain, enabling physicians to develop tailored treatment plans [2][6] - The technology employs proprietary signal processing techniques to extract and quantify chemical biomarkers, enhancing diagnostic clarity for physicians [6] Industry Engagement - Aclarion's participation in esteemed academic society meetings like ISPN highlights its commitment to innovation in the spine surgery and pain management ecosystem [3] - The panel discussion at ISPN underscored the importance of multidisciplinary approaches in diagnosing and treating back pain, showcasing Aclarion's collaborative efforts with leading experts [3][5]

Core Insights - Aclarion, Inc. will present at the 19th Annual LD Micro Main Event on October 20, 2025, at 12:00 PM PT, focusing on its healthcare technology solutions for chronic low back pain [2][3] Company Overview - Aclarion is a healthcare technology company utilizing Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to enhance clinical treatments [6] - The company is targeting the chronic low back pain market with its product Nociscan, which is the first evidence-supported SaaS platform designed to noninvasively help physicians differentiate between painful and non-painful discs in the lumbar spine [6] - Nociscan operates by receiving MRS data from MRI machines, processing it in the cloud to extract and quantify chemical biomarkers associated with disc pain, and providing insights to optimize treatment strategies [6] Event Details - The LD Micro Main Event XIX will take place from October 19 to 21, 2025, at the Hotel del Coronado in San Diego, California, featuring around 120 companies presenting in half-hour increments [4][5] - The event will include registration, keynote speakers, company presentations, one-on-one investor meetings, and a closing reception [4]

Core Insights - Aclarion, Inc. has been selected as a finalist in the Rising Star - Clinical Diagnostic Device category for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH, highlighting its innovative contributions to healthcare technology [1][4]. Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing Magnetic Resonance Spectroscopy (MRS) and proprietary AI algorithms to enhance clinical treatments [7]. - The company's flagship product, Nociscan, is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and non-painful discs in the lumbar spine [3][7]. Product Details - Nociscan transforms MR spectroscopy signals into objective biomarkers associated with disc pain, providing actionable insights for personalized treatment plans [3][7]. - An estimated 266 million people globally suffer from chronic low back pain, indicating a significant market opportunity for Aclarion's solutions [3]. Recognition and Impact - The recognition as a finalist from over 1,800 submissions underscores Aclarion's commitment to improving healthcare efficiency and equity through digital innovations [4][6]. - CEO Brent Ness emphasized that this acknowledgment reflects the company's vision and determination to make Nociscan widely available to those affected by chronic low back pain [4].

Core Insights - Aclarion, Inc. is leveraging biomarkers and proprietary augmented intelligence algorithms to assist physicians in identifying chronic low back pain locations through its platform, Nociscan [1][3] - The company recently presented at LSI Europe '25, highlighting Nociscan's potential to transform the chronic low back pain market and enhance shareholder value [2] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing Magnetic Resonance Spectroscopy (MRS) and proprietary signal processing techniques [3] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and non-painful discs in the lumbar spine [3] Technology and Clinical Evidence - Nociscan converts MR spectroscopy signals into objective biomarker data, aiding physicians in creating personalized treatment plans [5] - The ongoing 300-patient CLARITY randomized clinical trial aims to demonstrate that Nociscan-guided surgical decision-making can improve surgical outcomes beyond the current 54% industry success rate, with interim results expected in Q2 2026 [5] Financial Position - Aclarion has recently strengthened its balance sheet, providing the necessary capital to achieve commercial and clinical milestones [5]